- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.10. | Vaxcyte strikes up to $1B deal for fill-finish space at Thermo Fisher's NC production facility | ||
| 02.10. | Amgen charts late-stage win for Repatha in broad cardiovascular risk population | ||
| 02.10. | Acadia, e-therapeutics unveil rebrands to better represent their drugmaking missions | ||
| 02.10. | Vanda and the FDA make nice, agreeing to squash several disputes following appeals court win | ||
| 02.10. | AbbVie, BeOne end BTK blood cancer drug patent fight | ||
| 02.10. | Ansa snares $54.4M in series B financing to boost its DNA synthesis platform | ||
| 02.10. | Regulatory tracker: J&J's Tremfya picks up 2 pediatric approvals from FDA | ||
| 01.10. | Halozyme buys subcutaneous drug delivery peer Elektrofi for up to $900M | ||
| 01.10. | Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat | ||
| 01.10. | FDA snubs Cyprium-Sentynl drug for rare pediatric disease due to manufacturing issues | ||
| 01.10. | FDA avoids the worst amid government shutdown, but new applications put on hold | ||
| 01.10. | AbbVie charts next leg of US investment journey with $70M expansion in Mass. | ||
| 01.10. | Bayer consolidates global consumer health marketing, naming IPG as sole creative and media partner | ||
| 01.10. | Sanofi's German, French premises hit by EU probe amid vaccines market abuse concerns | ||
| 30.09. | Indivior to discontinue Opvee marketing after New York settlement | ||
| 30.09. | Novartis earns FDA's ire for 'misleading' romantic storyline of Fabhalta TV ad | ||
| 30.09. | Korea's Boryung looks to stir up new value in Sanofi's legacy chemo Taxotere with $205M rights buy | ||
| 30.09. | Pfizer plans to offer price concessions in Trump's 'most favored nation' push: reports | ||
| 30.09. | AnaptysBio plans to split biotech and Jemperli royalties into separate businesses | ||
| 30.09. | FDA official challenges safety, efficacy of Aurinia lupus med in now-deleted LinkedIn post targeting surrogate endpoints | ||
| 30.09. | Biogen supports Friedreich ataxia web series to get Bill Nye back in the lab | ||
| 30.09. | Rovi acquires BMS facility in Phoenix as part of 5-year, $250M manufacturing deal | ||
| 29.09. | New CDMO on the bloc: Rezon Bio debuts with 2 plants to tackle biologics contract work in Europe | ||
| 29.09. | Novartis, Boehringer DTC platforms slash prices for Cosentyx, Spiriva Respimat | ||
| 29.09. | AstraZeneca, Daiichi's Enhertu shows early breast cancer prowess with another trial win, topping Roche's Kadcyla |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .